<DOC>
	<DOCNO>NCT01400945</DOCNO>
	<brief_summary>The purpose study evaluate treatment Gastroesophageal Reflux Disease ( GERD ) patient ( age 18~75 ) endoscopically proven GERD treat AGSPT201 Tablet .</brief_summary>
	<brief_title>Efficacy Study AGSPT201 Tablet Treat Gastroesophageal Reflux Disease</brief_title>
	<detailed_description>This study 4,8 week , outpatient , multicenter , randomize , double-blinded , active drug comparative , therapeutic confirmatory clinical study evaluate efficacy safety AGSPT201 erosive esophagitis patient .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<criteria>age 18~75 year Patients whose esophageal lesion grade LA A grade ( The severity lesion classify LA classification ) Patients whose typical reflux symptom heartburn , acid regurgitation , acid reflux esophagus irritation past 3 month Symptoms least 2 day past 7 day PPI treatment within 4 week dose treatment H2 blocker , sucralfate , prokinase NSAID ( except low dose aspirin ) within 2 week dose . Patients whose history GI tract resection vagotomy . Barrett 's oesophagus great 3cm length highgrade dysplasia . Acid irrelevant Heartburn regurgitation . Zollinger Ellison syndrome Hypersensitive and/or allergy Pantoprazole and/or PPI Pregnancy lactation peptic ulcer serious hepatic renal , cardiac haematological disease . Patients participate clinical study past 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>GERD</keyword>
	<keyword>endoscopy</keyword>
	<keyword>LA grade</keyword>
	<keyword>heartburn</keyword>
</DOC>